Givinostat (hydrochloride monohydrate)

• UNSPSC Description:

  Givinostat hydrochloride monohydrate (ITF-2357 hydrochloride monohydrate) is a HDAC inhibitor with an IC50 of 198 and 157 nM for HDAC1 and HDAC3, respectively.

• Target Antigen:

  HDAC

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage;Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Givinostat_hydrochloride_monohydrate.html

• Solubility:

  DMSO : ≥ 100 mg/mL|H2O : 2.94 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  O=C(OCC1=CC=C2C=C(CN(CC)CC)C=CC2=C1)NC3=CC=C(C(NO)=O)C=C3.[H]Cl.O

• Molecular Weight:

  475.97

• References & Citations:

  [1]Li S, et al. Specific inhibition of histone deacetylase 8 reduces gene expression and production of proinflammatory cytokines in vitro and in vivo. J Biol Chem. 2015 Jan 23;290(4):2368-78.|[2]Wang YG, et al. Givinostat inhibition of hepatic stellate cell proliferation and protein acetylation. World J Gastroenterol. 2015 Jul 21;21(27):8326-39.|[3]Leoni F, et al. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med. 2005 Jan-Dec;11(1-12):1-15.J Mol Med (Berl). 2019 Aug;97(8):1183-1193.|Acta Pharmacol Sin. 2021 Apr 13.|Cell Prolif. 2021 May 24;e13072.|Commun Biol. 2021 Oct 29;4(1):1235.|J Am Chem Soc. 2024 Sep 27.|J Orthop Transl. 29 (2021) 106-112.|Neuroscience. 2021 Apr 13;S0306-4522(21)00185-8.|Patent. US20240252638A1.|SSRN. 2024 Mar 13.|Cell Death Dis. 2020 Sep 15;11(9):753.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  Launched

• CAS Number:

  732302-99-7